Percentage change from baseline in absolute lymphocyte counts at day 28 following treatment with CDP323 for 28 days (per protocol population).

a<p>n<i> = </i>14 per group except for CD34+ cells, where n = 5 for placebo and CDP323 1000 mg bid and n = 4 for CDP323 100 mg bid, CDP323 500 mg bid, and CDP323 1000 mg qd.</p>b<p>Least squares mean from analysis of variance (ANOVA).</p>c<p>Statistical comparisons were made using univariate ANOVA.</p><p>bid = twice daily; CI = confidence interval; NK = natural killer; NR = not reported (linear trend test for dose-response relationship was not statistically significant); qd = once daily.</p><p>Note: For all lymphocyte types, differences between the 500-mg bid and 1000-mg qd dosages were not statistically significant and are not displayed in this table.